Patents by Inventor Aviad Levin

Aviad Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Plant based functional materials
    Patent number: 12545786
    Abstract: The present invention relates to plant based materials, methods for their manufacture and biomaterials incorporating plant based materials.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: February 10, 2026
    Assignee: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: Marc Rodriguez Garcia, Tuomas Knowles, Aviad Levin, Ayaka Kamada
  • METHOD OF DETECTING PROTEIN AGGREGATES
    Publication number: 20250130246
    Abstract: The disclosure relates to methods of investigating protein aggregation reactions, in particular methods for detecting aggregates of a protein that are capable of seeding further protein aggregation. The methods allow not only understanding of aggregation reactions, but also provide means for detecting whether a sample from an individual comprises aggregate seeds.
    Type: Application
    Filed: November 1, 2022
    Publication date: April 24, 2025
    Inventors: Aviad LEVIN, Tuomas KNOWLES
  • PLANT BASED FUNCTIONAL MATERIALS
    Publication number: 20220169858
    Abstract: The present invention relates to plant based materials, methods for their manufacture and biomaterials incorporating plant based materials.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 2, 2022
    Inventors: Marc Rodriguez Garcia, Tuomas Knowles, Aviad Levin, Ayaka Kamada
  • HIV-1 integrase derived peptides and compositions
    Patent number: 9738878
    Abstract: Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: August 22, 2017
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Aviad Levin, Zvi Hayouka, Assaf Friedler, Abraham Loyter
  • HIV-1 INTEGRASE DERIVED PEPTIDES AND COMPOSITIONS
    Publication number: 20160032263
    Abstract: Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 4, 2016
    Inventors: Aviad Levin, Zvi Hayouka, Assaf Friedler, Abraham Loyter
  • HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
    Patent number: 9163067
    Abstract: Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: October 20, 2015
    Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd
    Inventors: Aviad Levin, Zvi Hayouka, Assaf Friedler, Abraham Loyter
  • HIV-1 INTEGRASE DERIVED STIMULATORY PEPTIDES INTERFERING WITH INTEGRASE -- REV PROTEIN BINDING
    Publication number: 20110257082
    Abstract: Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS.
    Type: Application
    Filed: October 1, 2009
    Publication date: October 20, 2011
    Inventors: Aviad Levin, Zvi Hayouka, Assaf Friedler, Abraham Loyter